BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30188568)

  • 1. A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid.
    Schauer F; Kern JS; Virtic O; Technau-Hafsi K; Meiss F; Thoma K; Athanasiou I; Sitaru C; Di Zenzo G; Izumi K; Nishie W; Shimizu H; Bruckner-Tuderman L; Kiritsi D
    Br J Dermatol; 2019 Jan; 180(1):231-232. PubMed ID: 30188568
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
    Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
    J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
    [No Abstract]   [Full Text] [Related]  

  • 3. Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.
    Menzinger S; Kaya G; Schmidt E; Fontao L; Laffitte E
    Acta Derm Venereol; 2018 Feb; 98(2):284-286. PubMed ID: 29136264
    [No Abstract]   [Full Text] [Related]  

  • 4. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.
    Fania L; Didona D; Pacifico V; Mariotti F; De Luca N; Abeni D; Mazzanti C; Di Zenzo G; Didona B
    J Dermatol; 2018 Sep; 45(9):1135-1140. PubMed ID: 30007013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythema Multiforme-Like Bullous Pemphigoid.
    Imbernón-Moya A; Aguilar A; Burgos F; Gallego MÁ
    Actas Dermosifiliogr; 2016 Oct; 107(8):689-91. PubMed ID: 27048923
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE.
    Salz M; Haeberle S; Hoffmann J; Enk AH; Hadaschik EN
    J Dermatol Sci; 2017 Sep; 87(3):309-311. PubMed ID: 28823642
    [No Abstract]   [Full Text] [Related]  

  • 7. Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients.
    Ma L; Wang M; Wang X; Chen X; Zhu X
    J Dermatol Sci; 2015 Apr; 78(1):76-7. PubMed ID: 25797173
    [No Abstract]   [Full Text] [Related]  

  • 8. Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.
    Kamiya K; Aoyama Y; Noda K; Miyake T; Yamaguchi M; Hamada T; Tokura Y; Iwatsuki K
    J Dermatol Sci; 2015 Apr; 78(1):77-9. PubMed ID: 25771164
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivities and utility of non-invasive serological tests in the diagnosis of bullous pemphigoid.
    Yew YW; Tey HL
    Int J Dermatol; 2016 Sep; 55(9):e510-1. PubMed ID: 27028937
    [No Abstract]   [Full Text] [Related]  

  • 10. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
    Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
    Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
    [No Abstract]   [Full Text] [Related]  

  • 11. Serological investigation of bullous scabies and review of the published work.
    Kokubu H; Takahashi T; Tateishi C; Tsuruta D; Hashimoto T; Tanaka T; Fujimoto N
    J Dermatol; 2019 Sep; 46(9):e324-e325. PubMed ID: 30969443
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of BP230 autoantibodies in bullous pemphigoid.
    Shih YC; Wang B; Yuan H; Zheng J; Pan M
    J Dermatol; 2020 Apr; 47(4):317-326. PubMed ID: 32048350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230.
    Miyashita K; Iioka H; Miyagawa F; Ishii N; Hashimoto T; Asada H
    Eur J Dermatol; 2018 Apr; 28(2):248-250. PubMed ID: 29378676
    [No Abstract]   [Full Text] [Related]  

  • 14. Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium.
    Gutjahr A; Heck F; Emtenani S; Hammers AK; Hundt JE; Muck P; Siegel DL; Schmidt E; Stanley JR; Zillikens D; Hammers CM
    Br J Dermatol; 2019 Sep; 181(3):593-594. PubMed ID: 31124130
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunoglobulin E and bullous pemphigoid.
    Cozzani E; Gasparini G; Di Zenzo G; Parodi A
    Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.
    Fairley JA; Baum CL; Brandt DS; Messingham KA
    J Allergy Clin Immunol; 2009 Mar; 123(3):704-5. PubMed ID: 19152970
    [No Abstract]   [Full Text] [Related]  

  • 17. Case of atypical bullous pemphigoid with generalized pruritus and eczema as the prodrome for 10 years.
    Ikeda T; Okamoto K; Furukawa F
    J Dermatol; 2012 Aug; 39(8):720-1. PubMed ID: 22011062
    [No Abstract]   [Full Text] [Related]  

  • 18. Bullous pemphigoid-like eruption subsequent to scabies: bullous scabies or bullous pemphigoid?
    Huang MX; Li ZS; Luo DQ; Lin Q
    G Ital Dermatol Venereol; 2015 Jun; 150(3):337-9. PubMed ID: 25658439
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-desmogleins autoantibodies detected by ELISA and blotting in bullous pemphigoid: what do they mean?
    Julio T; Vernal S; Turatti A; Roselino AM
    Int J Dermatol; 2018 Jan; 57(1):124-127. PubMed ID: 29152717
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.